TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28706103
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D metabolites and associated hormones measurements in AKI patients
Study: 28706103
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D metabolites and associated hormones measurements in non-AKI patients
Study: 28706563
Drug: OFC (6/25-12/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFC (6/25-12/50 mg/day olanzapine/fluoxetine)
Study: 28707359
Drug: Pedometer tracking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer tracking of daily steps
Study: 28708962
Drug: Ad5-EBOV (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-EBOV (one shot intramuscular injection)
Study: 28708962
Drug: Ad5-EBOV (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-EBOV (high-dose group)
Study: 28709412
Drug: Propranolol 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.2% eye micro-drops treatment until retinal vascularization is completed, but for no longer than 90 days.
Study: 28709439
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic management (RAM)
Study: 28710110
Drug: Patient-tailored complementary/integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-tailored complementary/integrative medicine (CIM) programme, with adherence defined as attending ≥4 CIM treatments, with ≤30 days between each session.
Study: 28710747
Drug: CART-HER2 cells
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CART-HER2 cells infused after conditioning treatment with nab-paclitaxel (100-200 mg/m2)
Study: 28711173
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RT-PCR and ddPCR
Study: 28712533
Drug: 60Gy intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60Gy intensity modulated radiotherapy with concurrent weekly intravenous cisplatinum
Study: 28713062
Drug: Second-generation colon
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation colon capsule endoscopy (CCE-2)
Study: 28713365
Drug: Detection and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection and quantification of immune compounds in human milk
Study: 28713581
Drug: Elevated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated protein intake (EPI, 20% of daily calorie intake)
Study: 28713581
Drug: Recommended protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended protein intake (RPI, 10% of daily calorie intake)
Study: 28716801
Drug: ACR+ve diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR+ve diabetes mellitus patients after 1-year treatment with renin-angiotensin-aldosterone blockade
Study: 28716862
Drug: Autologous gene
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous gene therapy using a self-inactivating lentiviral vector (LV-w1.6 WASp) after reduced-intensity conditioning
Study: 28717036
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care workers (HCWs) wearing gowns and gloves (G&G) during usual care activities.
Study: 28717516
Drug: Intravenous Darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Darbepoetin (DA)
Study: 28717516
Drug: Intravenous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Epoetin (EPO)
Study: 28719652
Drug: HIVconsv vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVconsv vaccine (plasmid DNA, simian adenovirus, poxvirus MVA)
Study: 28719652
Drug: HIVconsv vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVconsv vaccine
Study: 28720129
Drug: RTW-focused approach
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTW-focused approach in therapy
Study: 28720129
Drug: Baseline work
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline work ability and expectancy of future work ability, history of psychiatric treatment, focus on RTW in treatment
Study: 28720129
Drug: Improvement in
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improvement in expectations of future work ability at post-treatment
Study: 28720549
Drug: HSV-1/ganciclovir treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV-1/ganciclovir treatment.
Study: 28721067
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pasireotide long-acting release (LAR) i.m.
Study: 28721067
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pasireotide long-acting release (LAR) i.m.
Study: 28724380
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to and use of TVs, cell phones, tablets, and video games in the bedroom
Study: 28724445
Drug: Combined plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined plasmapheresis (PE) and allogeneic mesenchymal stem cells transplantation (MSCT) therapy
Study: 28724646
Drug: Trimethylamine treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethylamine treatment, dosage and duration not specified
Study: 28724795
Drug: ALX receptor
Normalized name: ALX-009
DrugBank: ALX-009 (DB17916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALX receptor expression in BAL macrophages
Study: 28725257
Drug: Breastfeeding relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfeeding relaxation therapy (daily audio recording during breastfeeding)
Study: 28725594
Drug: Weekly infusions
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly infusions of ascorbic acid (AA); week 1: 5 g, week 2: 30 g, weeks 3-12: 60 g
Study: 28725594
Drug: Weekly infusions
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly infusions of ascorbic acid (AA)
Study: 28727583
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine and bupivacaine HCl mixture (266 mg liposomal bupivacaine and 125 mg 0.25% bupivacaine HCl with epinephrine 1:300,000)
Study: 28730692
Drug: Cross-sex hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormone therapy (CSHT) for trans men
Study: 28730692
Drug: Cross-sex hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormone therapy (CSHT) for trans women
Study: 28733294
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (specific details not provided)
Study: 28733943
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections (70 to 150 U per session, targeted to pericranial myofascial sites)
Study: 28733943
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections
Study: 28735291
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low coronary artery calcium score and low high-sensitivity cardiac troponin T
Study: 28736443
Drug: CLOCK 3111C
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLOCK 3111C carriers (CC and TC)
Study: 28736443
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss during treatment program
Study: 28739783
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg, once daily)
Study: 28740367
Drug: Comprehensive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive lifestyle changes and/or metformin treatment
Study: 28746812
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells (AD MSCs)
Study: 28747274
Drug: On-demand PrEP
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg) taken before and after sexual intercourse
Study: 28747857
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cessation intervention (treatment arm) with nicotine patches for 8 weeks
Study: 28747857
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavioral therapy (comparison arm) with nicotine patches for 8 weeks
Study: 28750271
Drug: LY2780301 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 500 mg QD plus gemcitabine 750 mg/m²
Study: 28750271
Drug: LY2780301 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 400 mg QD plus gemcitabine 1000 mg/m²
Study: 28750271
Drug: LY2780301 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 500 mg QD plus gemcitabine 1000 mg/m²
Study: 28750271
Drug: LY2780301 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 400 mg QD plus gemcitabine 750 mg/m²
Study: 28750429
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with diabetes
Study: 28750608
Drug: Anti-arrhythmic drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arrhythmic drug therapy
Study: 28750659
Drug: 8 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles of modified FOLFIRINOX (oxaliplatin 85 mg/m2, details of other drugs not provided)
Study: 28750659
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus hypofractionated radiation therapy
Study: 28751088
Drug: Hypoalbuminemia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoalbuminemia group (Hypo-AG, serum albumin <28 g/L)
Study: 28751088
Drug: Marginal hypoalbuminemia
Normalized name: Culex marginalis
DrugBank: Culex pipiens (DB14165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marginal hypoalbuminemia group (Margin-AG, serum albumin 28-34.9 g/L)
Study: 28751088
Drug: Normal albuminemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal albuminemia group (Normal-AG, serum albumin ≥35 g/L)
Study: 28751247
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 or 160 mg daily)
Study: 28752370
Drug: L-NMMA and
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA and diclofenac
Study: 28752679
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous stimulated bone marrow stem cells (BM-SC)
Study: 28752679
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (Control group)
Study: 28752805
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs supplementation (1800 mg daily for 12 weeks, containing 1206 mg eicosapentaenoic acid and 609 mg docosahexaenoic acid)
Study: 28753747
Drug: Degarelix therapy
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix therapy for 7 months
Study: 28753830
Drug: Intracavernous autologous
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous autologous bone marrow mononuclear cells (BM-MNCs) injected at an optimal dose of 1×10^6 cells.
Study: 28754494
Drug: CV7201 (mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly by needle-syringe or needle-free devices, doses ranging from 80-640 μg, with three doses and a booster after 1 year.
Study: 28754494
Drug: CV7201 (mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly, doses of 80 μg or 160 μg intradermally and 200 μg or 400 μg intramuscularly.
Study: 28754494
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 80 μg CV7201 administered needle-free intradermally after 1 year.
Study: 28754494
Drug: Intradermal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal or intramuscular needle-syringe injection of CV7201.
Study: 28754534
Drug: Drug-eluting beads
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting beads loaded with doxorubicin (DEBDOX)
Study: 28755389
Drug: Dulaglutide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 2.0 mg for 6 months
Study: 28755389
Drug: Dulaglutide therapy
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide therapy
Study: 28756183
Drug: Menaquinone-7 (vitamin
Normalized name: menaquinone-7 (vitamin K2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (vitamin K2) supplementation (360 μg once daily) for 8 weeks
Study: 28761581
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release, bilayer tablets for 7 consecutive days
Study: 28761581
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release
Study: 28761651
Drug: Self-adjusted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-adjusted medication during fasting
Study: 28761685
Drug: Dual-therapy stent
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-therapy stent
Study: 28761750
Drug: Aflibercept in
Normalized name: aflibercept Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Study: 28761750
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Study: 28762099
Drug: Multidisciplinary childhood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary childhood obesity treatment programme
Study: 28763344
Drug: Desvenlafaxine 50-100
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50-100 mg/day for 8 weeks
Study: 28764748
Drug: Ganetespib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (150 mg/m) in combination with weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m)
Study: 28764748
Drug: Ganetespib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (150 mg/m)
Study: 28764836
Drug: Long-term aspirin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term aspirin treatment cessation before surgery
Study: 28764836
Drug: Previous discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous discontinuation of aspirin treatment
Study: 28764836
Drug: Unawareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unawareness of the reason for aspirin use
Study: 28765502
Drug: Neoadjuvant 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant 5-fluorouracil (5-FU) 225 mg/m², oxaliplatin, and lapatinib in combination with radiation therapy
Study: 28765502
Drug: Neoadjuvant 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant 5-fluorouracil (5-FU) in combination with radiation therapy
Study: 28766535
Drug: ALL-2009 protocol
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALL-2009 protocol (non-intensive, continuous cytotoxic treatment)
Study: 28768493
Drug: Supportive text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive text messages (twice-daily for 3 months)
Study: 28768681
Drug: CALM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM therapy
Study: 28768756
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg plus aspirin 325 mg (loading dose) followed by ticagrelor 90 mg BID plus aspirin 81 mg QD (maintenance therapy)
Study: 28768822
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (1.0 g/kg every 3 weeks for up to 52 weeks)
Study: 28769925
Drug: RO5459072, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5459072, a small molecule inhibitor of Cathepsin S
Study: 28770543
Drug: Virtual-reality-based neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual-reality-based neurocognitive stimulation sessions (20-min daily sessions)
Study: 28771673
Drug: Single-agent lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent lenalidomide
Study: 28771673
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice single-agent therapy
Study: 28771889
Drug: Pralatrexate, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralatrexate, given i.v. weekly for 6 weeks of a 7-week cycle
Study: 28771889
Drug: Concurrent vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent vitamin B, given alongside pralatrexate
Study: 28772110
Drug: Luteinising hormone
Normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinising hormone (LH)
Study: 28772306
Drug: Lung adenocarcinoma
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung adenocarcinoma treatment, specific intervention details not available.
Study: 28774277
Drug: Genomic variations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic variations in anthracycline metabolism and myocardial response to injury
Study: 28778175
Drug: Dual-diagnosis motivational
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-diagnosis motivational interviewing (DDMI) and integrated group therapy (IGT)
Study: 28778448
Drug: PF-00547659 anti-MAdCAM-1
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 anti-MAdCAM-1 therapy
Study: 28778554
Drug: Integrated Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Care for patients with psychotic disorders (treatment for ≥4 years)
Study: 28778611
Drug: Complete vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete vaccination cohort (2 doses of RV1)
Study: 28778611
Drug: Incomplete vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete vaccination cohort (1 dose of RV1)
Study: 28778843
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus daily text message reminders for medication adherence
Study: 28778843
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus 4 daily text messages for exercise adherence
Study: 28778946
Drug: Subcutaneous electrocardiographic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous electrocardiographic monitors (St. Jude CONFIRM-AF) implanted in patients
Study: 28779027
Drug: 14-day gluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day gluten challenge with 5.7 grams per oral gluten daily
Study: 28780030
Drug: Lutonix 035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutonix 035 drug-coated balloon (DCB)
Study: 28780401
Drug: Task-concurrent functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-concurrent functional connectivity dynamics
Study: 28784593
Drug: Domiciliary VR-based
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domiciliary VR-based therapy
Study: 28784593
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (home-based occupational therapy)
Study: 28784598
Drug: Vorinostat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (100 mg twice daily) started on day -10 and continued through day +100 post-HCT with tacrolimus and methotrexate for GVHD prophylaxis.
Study: 28784598
Drug: Vorinostat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (100 mg twice daily) with tacrolimus and methotrexate.
Study: 28785295
Drug: ~60 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: ~60 g/d almonds (ALM)
Study: 28786339
Drug: Request for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Request for suspension or reduction in sentence on medical grounds (n=48)
Study: 28786987
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch therapy for 24 weeks in patients with minimal WMHs (group 1)
Study: 28786987
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch therapy for 24 weeks in patients with moderate WMHs (group 2)